Search

everythinglearnresearchcommunity

for

Search:↓

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.

CTP-543 is generally safe for treating alopecia areata.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

The drug combination was safe and showed promise in treating advanced tumors.

HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.

A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

MNC-QQ cell therapy improved hair growth and quality of life in men with androgenic alopecia without adverse effects.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Increased EGFR gene variations may predict chemotherapy outcomes in small cell lung cancer patients.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

The treatment was not recommended due to limited effectiveness and significant side effects.

Patients with non-small-cell lung cancer need significant survival gains to accept severe side effects.

Targeted radionuclide therapy shows promise for improving head and neck cancer treatment but needs more research.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.